⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 16, 2024Open Access

Supplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Caroline E. Gleason Mark A. Dickson Mary E. Klein Cristina R. Antonescu Rodrigo Gularte‐Mérida Marimar Benitez Juliana I. Delgado Raghu P. Kataru Mark Wei Yi Tan Martina Bradić Travis E. Adamson Kenneth Seier Allison L. Richards Marta Palafox Eric Chan Sandra P. D’Angelo Mrinal M. Gounder Mary Louise Keohan Ciara M. Kelly Ping Chi Sujana Movva Jonathan Landa Aimeé M. Crago Mark T.A. Donoghue Li‐Xuan Qin Violetta Serra Mesruh Turkekul Afşar Barlas Daniel M. Firester Katia Manova‐Todorova Babak J. Mehrara Marta Kovatcheva Nguan Soon Tan Samuel Singer William D. Tap Andrew Koff

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Relationship between CDH18 expression, MDM2 downregulation, and ANGPTL4 mRNA expression in patients treated with abemaciclib

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gleason et al. (2024) studied this question.

synapsesocial.com/papers/68e78e3ab6db6435877001e0 https://doi.org/10.1158/1078-0432.25232584.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S16 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024
2Supplementary Figure S12 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024
3Supplementary Figure S12 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024
4Supplementary Figure S11 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024
5Supplementary Figure S11 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024
6Supplementary Figure S13 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024
7Supplementary Figure S13 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024
8Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma2024